Spots Global Cancer Trial Database for A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer.

Official Title: ANV419 First in Human Study Phase 1: Open-label, Dose Escalation Study of ANV419 as Single Agent and in Combination With Ipilimumab in Patients With Relapsed/Refractory Advanced Solid Tumors

Study ID: NCT04855929

Conditions

Advanced Solid Tumor

Adult Disease

Lung Cancer

Interventions

ANV419

Ipilimumab

Study Description

Brief Summary: The purpose of this study is to test the safety and efficacy of ANV419 (single agent) and in combination with ipilimumab in patients with relapsed/refractory advanced solid tumors.

Detailed Description: The purpose of this First-in-Human, open-label, dose escalation study is to assess the initial safety and efficacy profile of ANV419 intravenous infusion alone and in combination with ipilimumab in patients with advanced solid tumours. It will evaluate the safety and tolerability of ANV419 alone and in combination with ipilimumab and, the safest and best dose of ANV419 when used alone or in combination.